Management of Hypertension:JNC 8 and Beyond
作者机构：Division of Cardiovascular MedicineDepartment of Internal MedicineUniversity of CaliforniaDavisSchool of MedicineSacramentoCA 95817USA
出 版 物：《Cardiovascular Innovations and Applications》 (心血管创新与应用（英文）)
年 卷 期：2016年第1卷第B9期
页 面：409-416页
主 题：hypertension JNC 7 JNC 8 cardiovascular risk factors SPRINT
摘 要：Hypertension is a leading risk factor for cardiovascular disease,the leading cause of death and morbidity in our society and on a global *** components of cardiovascular disease include stroke,coronary artery disease,heart failure,and chronic kidney disease,in all of which hypertension plays a major *** risk of these complications increases directly and linearly with systolic blood pressure starting at 115 *** usually asymptomatic,hypertension is readily detectable on physical examination and is amenable to both lifestyle modifi cation and pharmacologic treatment in most ***,large proportions of the hypertensive population remain undetected and *** guidelines have been issued during the past few decades to promote detection and optimal *** the increase in risk with systolic blood pressure greater than 115 mmHg,the generally accepted threshold for diagnosis and treatment has been systolic blood pressure greater than 139 mmHg and diastolic blood pressure greater than 80 mmHg because until recently treatment to lower levels has been associated with an unfavorable relation between clinical benefi t and *** the past several years,new guidelines,advisories,commentaries,and clinical trials have provided evidence for a potential change in current recommendations for the management of *** this regard,the long-awaited eighth report of the Joint National Committee on the Prevention,Detection,Evaluation,and Treatment of High Blood Pressure recommended patients older than 60 years be treated to a systolic blood pressure of less than 150 mmHg,which has generated considerable controversy and *** striking fi ndings of the Systolic Blood Pressure Intervention Trial(SPRINT)have received considerable attention because of the demonstration that intensive therapy to a target systolic blood pressure below 120 mmHg decreases cardiovascular mortality and morbidity more than less intensive treatment to
维普期刊数据库